| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/26/2006 | EP1682160A2 Composition and method for treating bezoar and trichobezoar |
| 07/26/2006 | EP1682159A1 Immunomodulating compositions and uses therefor |
| 07/26/2006 | EP1682158A1 Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders |
| 07/26/2006 | EP1682157A1 Combinations comprising ampa receptor antagonists for the treatment of schizophrenia |
| 07/26/2006 | EP1682156A1 Strontium-based complexes, pharmaceutical compositions and dietetic products |
| 07/26/2006 | EP1682155A1 Analgesia method |
| 07/26/2006 | EP1682154A1 Process for preparing phytosterol dispersions for application in beverages |
| 07/26/2006 | EP1682153A2 Methods of modulating angiogenesis and cancer cell proliferation |
| 07/26/2006 | EP1682152A2 Compositions and methods for treatment of nervous system disorders |
| 07/26/2006 | EP1682151A1 Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) en-2-yl)alkyl]phosphonic acid and derivatives |
| 07/26/2006 | EP1682150A2 Compositions and methods for inducing cell dedifferentiation |
| 07/26/2006 | EP1682149A2 Injectable gabapentin compositions |
| 07/26/2006 | EP1682148A1 Use of bh4 for the treatment of respiratory diseases |
| 07/26/2006 | EP1682147A1 Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| 07/26/2006 | EP1682146A1 Antimycotic nail polish formulations comprising substituted 2-aminothiazoles as an active substance |
| 07/26/2006 | EP1682145A1 1-alkylpiperazinyl-pyrrolidin-2,5-dione derivatives as adrenergic receptor antagonists |
| 07/26/2006 | EP1682144A1 Pharmaceutical formulations containing flavouring substances with improved pharmaceutical properties |
| 07/26/2006 | EP1682143A2 Combinations comprising an hsp90 inhibitor and a phophodiesterase inhibitor for treating or preventing neoplasia |
| 07/26/2006 | EP1682142A2 M3 muscarinic acetylcholine receptor antagonists |
| 07/26/2006 | EP1682141A1 4-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain |
| 07/26/2006 | EP1682140A2 Methods of use of thrombin receptor antagonists |
| 07/26/2006 | EP1682139A1 Preparation of pharmaceutical salts of 1, 4 - bipiperidine |
| 07/26/2006 | EP1682138A2 Heterocyclic inhibitors of mek and methods of use thereof |
| 07/26/2006 | EP1682137A1 Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain |
| 07/26/2006 | EP1682136A1 Therapeutic compounds and uses thereof |
| 07/26/2006 | EP1682135A1 Ccr-2 antagonist salt |
| 07/26/2006 | EP1682134A2 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| 07/26/2006 | EP1682133A1 Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux |
| 07/26/2006 | EP1682132A1 Transscleral delivery |
| 07/26/2006 | EP1682131A1 Cci-779 for treating mantle cell lymphoma |
| 07/26/2006 | EP1682130A1 Novel compositions |
| 07/26/2006 | EP1682129A1 N-thiazol-2-yl-benzamide derivatives |
| 07/26/2006 | EP1682128A2 Process and formulation containing epothilones and analogs thereof |
| 07/26/2006 | EP1682127A1 Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
| 07/26/2006 | EP1682126A1 Substituted benzazoles and use thereof as inhibitors of raf kinase |
| 07/26/2006 | EP1682125A1 Multiple active agents such as anthelmintics sustained release delivery |
| 07/26/2006 | EP1682124A1 Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof |
| 07/26/2006 | EP1682123A1 Cancer treatment method |
| 07/26/2006 | EP1682122A1 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic |
| 07/26/2006 | EP1682121A1 Use of crth2 antagonist compounds in therapy |
| 07/26/2006 | EP1682120A2 Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 07/26/2006 | EP1682119A1 Discodermolide compositions |
| 07/26/2006 | EP1682118A1 Ectoparasiticidal formulations of spinosyns and azole pesticides |
| 07/26/2006 | EP1682117A1 2-azetidinones as anti-hypercholesterolemic agents |
| 07/26/2006 | EP1682116A1 Method for preparing submicron particles of paclitaxel |
| 07/26/2006 | EP1682115A2 Hif-1 inhibitors and methods of use thereof |
| 07/26/2006 | EP1682114A2 Methods of lowering lipid levels in a mammal |
| 07/26/2006 | EP1682113A1 Inhibitor imaging agents |
| 07/26/2006 | EP1682112A1 Use of sulfonamide compounds for the treatment of diabetes and/or obesity |
| 07/26/2006 | EP1682111A1 Enos transcription enhancers for use in the cell therapy of ischemic heart diseases |
| 07/26/2006 | EP1682110A1 Pharmaceutical composition consisting of a beta-3 adrenoceptor agonist and an alpha agonist |
| 07/26/2006 | EP1682109A1 The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic as peptides in amyloidopathies |
| 07/26/2006 | EP1682108A1 Reversing, postponing or preventing the occurrence of gtn tolerance and/or generation of reactive oxygen species from mitochondria |
| 07/26/2006 | EP1682107A1 Anti-tumour terpene compounds |
| 07/26/2006 | EP1682105A2 N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity |
| 07/26/2006 | EP1682104A2 Migraine treatments including isovaleramide compounds and serotonin agonists |
| 07/26/2006 | EP1682103A1 Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation |
| 07/26/2006 | EP1682102A2 Multi-layer transdermal drug delivery device |
| 07/26/2006 | EP1682100A2 Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same |
| 07/26/2006 | EP1682098A1 Colonic purgative composition with soluble binding agent |
| 07/26/2006 | EP1682096A1 Process for preparing clopidogrel compositions |
| 07/26/2006 | EP1682095A1 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| 07/26/2006 | EP1682093A1 Process for preparing a co-precipitate of a non-crystalline solid drug substance |
| 07/26/2006 | EP1682090A1 Buccal, polar and non-polar spray containing ondansetron |
| 07/26/2006 | EP1682088A1 Oral microemulsion composition comprising biphenyldimethyldicarboxylate and silybin |
| 07/26/2006 | EP1682087A1 Chewable tablet |
| 07/26/2006 | EP1682086A2 Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof |
| 07/26/2006 | EP1682081A2 Process for manufacture of metoprolol and salts thereof |
| 07/26/2006 | EP1682076A2 Inhibitors of coronavirus protease and methods of use thereof |
| 07/26/2006 | EP1682073A2 Method and antisense composition for selective inhibition of hiv infection in hematopoietic cells |
| 07/26/2006 | EP1682072A2 AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT |
| 07/26/2006 | EP1682060A1 Enhancing transdermal administration of hydrophilic drugs |
| 07/26/2006 | EP1682012A2 Composition and apparatus for transdermal delivery |
| 07/26/2006 | EP1681983A2 Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
| 07/26/2006 | EP1681925A1 Insect repellent compositions comprising dihydronepetalactone |
| 07/26/2006 | EP1681922A2 Method for treating athlet s foot |
| 07/26/2006 | EP1601672B1 Triazolo-pyridines as anti-inflammatory compounds |
| 07/26/2006 | EP1549713B1 Synergistic uv absorber combination |
| 07/26/2006 | EP1549649B1 Process for preparing haloalkyl pyrimidines |
| 07/26/2006 | EP1534721B1 Process for controlling the hydrate mix of the disodium salt of fosfluconazole |
| 07/26/2006 | EP1527063B1 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| 07/26/2006 | EP1513863B1 Platinum complexes containing chemically modified bile acids, having antitumor activity |
| 07/26/2006 | EP1513839B1 3-substituted quinuclidines and their use |
| 07/26/2006 | EP1503747B1 Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders |
| 07/26/2006 | EP1458384B1 Amlopidine bezylate tablets with improved stability |
| 07/26/2006 | EP1448552B1 Quinoline derivatives, process for preparing them and use for the treatment of diseases mediated by s-cd23 |
| 07/26/2006 | EP1414447B1 Use of thiazole derivatives for preparing a medicine for protecting mitochondria |
| 07/26/2006 | EP1397105B1 Compositions for inhibiting angiogenesis |
| 07/26/2006 | EP1392329B1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 07/26/2006 | EP1390543B1 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 07/26/2006 | EP1383539B1 Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof |
| 07/26/2006 | EP1381686B1 Inactivation of genes of the mep pathway |
| 07/26/2006 | EP1373215B1 Geldanamycin derivatives useful for treating cancer |
| 07/26/2006 | EP1368299B1 Substituted c-cyclohexylmethylamine derivatives |
| 07/26/2006 | EP1359905B1 Use of mglur5 antagonists for the treatment of pruritic conditions |
| 07/26/2006 | EP1357906B1 Blockade of sodium channels by phenol derivatives |
| 07/26/2006 | EP1353919B1 Novel quinuclidine derivatives and medicinal compositions containing the same |
| 07/26/2006 | EP1353687B1 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof |
| 07/26/2006 | EP1349578B1 Medicinal association of a biguanine (metformin) and arginine |
| 07/26/2006 | EP1349457B1 Liquid antimicrobial compositions |